The Week in Review: June 22 – June 29, 2018

Friday, June 29, 2018 News Recap: Canada: Boomer Moms At High Risk For Hep C, Says Doctor. A quarter million Canadians are believed to have the hepatitis C virus at this moment, and many have no idea. Dr. Rod Russell says it’s really baby boomers at the highest risk, and to be specific, it’s our mothers, the women who gave birth before 1992, especially if they had blood transfusions during pregnancy. Their children are also at risk because if the mo...

DAA Therapy Highly Efficacious for HCV Treatment in Older Adults

Direct-acting antiviral (DAA) therapy is highly efficacious for the treatment of hepatitis C virus (HCV) infection in individuals >65 years; however, those 75 years are more likely to be at risk for significant drug-drug interactions and experience adverse events during therapy, according to a retrospective study published in the Journal of the American Geriatrics Society. Sustained virologic response rate was 97.7% in individuals aged 65 to 74 years a

Efficacy of Direct-Acting Antivirals for HCV Clearance in Older Adults

Data published in the Journal of the American Geriatrics Society suggest direct-acting antivirals (DAAs) are safe and effective at achieving a sustained virologic response in older adults with hepatitis C virus (HCV)-related fibrosis or cirrhosis. HCV clearance is essential in improving disease outcomes in the general population, but data on reducing liver-related complications and increasing life expectancy in older adults are limited. The researchers

The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Direct-acting Antivirals Effective in Older Patients with Hepatitis C

Treatment of hepatitis C virus (HCV) with sofosbuvir-based direct acting antivirals (DAAs) was recently found as effective and well-tolerated in elderly patients as it was in younger patients in previous development trials. "Historically, older patients have been underrepresented in studies evaluating the efficacy and safety of HCV treatment due to poor tolerability and suboptimal response to interferon-based regimens," the researchers wrote. Satapathy